[
  {
    "ts": null,
    "headline": "4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer",
    "summary": "4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evalu",
    "url": "https://finnhub.io/api/news?id=d519722a430166cd826e99090a64d0bf0075c147c33083a42a4d4cf55cc68436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769101200,
      "headline": "4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer",
      "id": 138205891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evalu",
      "url": "https://finnhub.io/api/news?id=d519722a430166cd826e99090a64d0bf0075c147c33083a42a4d4cf55cc68436"
    }
  }
]